Investors
Advancing Breast Cancer Screening With A Non-invasive Blood Test
ASX:BDX
About BCAL Diagnostics
BCAL Diagnostics Limited is an Australian biotechnology company, founded in 2010 and headquartered in Sydney, Australia, and listed on the Australian Securities Exchange (ASX: BDX). For over a decade, BCAL has been developing early, non-invasive blood test based diagnostic technologies designed to complement mammograms and improve breast cancer screening outcomes for women worldwide.
BCAL’s NATA-accredited commercial laboratory, equipped with advanced Liquid Chromatography Mass Spectrometry (LCMS) technology, supports both ongoing research and the commercial rollout of its diagnostic test.
In 2025 BCAL entered into an exclusive licence partnership with US-based ClearNote Health Inc., providing access to the Avantect® pancreatic and ovarian cancer early detection blood tests across Australia. These epigenomics-based tests leverage artificial intelligence and advanced genomic analysis, and expand BCAL’s diagnostic portfolio beyond breast cancer and addressing cancers that are challenging to identify in early stages.
Through strategic collaborations with pathology networks and clinical partners, BCAL aims to provide nationwide access to innovative diagnostics that support earlier cancer detection regardless of location.
ASX Announcements
Financial Reports
Latest Presentations
Corporate Governance
The Board of BCAL Diagnostics is committed to transparency, integrity, and accountability, ensuring our governance framework supports long-term growth and sustainability.
A strong, values-based governance structure is fundamental to our company, guiding ethical decision-making and responsible business practices. We align with best practice principles and the ASX Corporate Governance Council’s recommendations to uphold these standards.
For more details, download our key policies below.
Code of Conduct
Audit and Risk Management Committee
Board Charter
Diversity and Inclusion Policy
Privacy Policy
Remuneration and Nominations Committee Charter
Corporate Governance Statement
Securities Trading Policy
Continuous Disclosure Policy
Whistleblower Policy
Shareholder Communications Policy
Anti-bribery and Corruption Policy
Join Our Team in Transforming Breast Cancer Diagnostics
We invite you to take the next step:
- Support our mission by exploring investment opportunities with BCAL Diagnostics (ASX: BDX).
Contact our Investors Relations Team today.